Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 5,399 matching trials from the live ClinicalTrials.gov search.

Filters: Tucson, Arizona Clear all

Conditions: Overactive Bladder
Interventions: Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose, Matching Placebo; Drug
Lead sponsor: Velicept Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 1,413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 77
States / cities: Birmingham, Alabama • Guntersville, Alabama • Saraland, Alabama + 61 more

Conditions: Growth and Tolerance
Interventions: Control Formula, Experimental Formula 1, Experimental Formula 2, Human Milk; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: Up to 5 Days
Enrollment: 424 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 23
States / cities: Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 19 more

Conditions: Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine
Interventions: Priorix, M-M-R II, Varivax, Havrix, Prevnar 13; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 1,742 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 80
States / cities: Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 69 more

Conditions: Healthy Aging
Interventions: Continuous theta burst transcranial magnetic stimulation; Device
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 80 Years
Enrollment: 248 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Foot Ulcer, Diabetes
Interventions: KC-002, Conventional Wound Therapy; Device · Other
Lead sponsor: KeraCure; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 21
States / cities: Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more

Conditions: Knee Osteoarthritis
Interventions: Durolane, PBS; Device
Lead sponsor: Galderma R&D; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 25
States / cities: Anniston, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more

Conditions: Cystic Fibrosis
Interventions: Cavosonstat, Placebo; Drug
Lead sponsor: Nivalis Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 46
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 42 more

Conditions: Head and Neck Cancer
Interventions: cetuximab, intensity-modulated radiation therapy; Biological · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2029
U.S. locations: 250
States / cities: Birmingham, Alabama • Tucson, Arizona • Auburn, California + 191 more

Conditions: Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
Interventions: Durvalumab, Tremelimumab, Cisplatin (dose level 4), Cisplatin (dose level 3), Carboplatin (dose level 1), Carboplatin (dose level 2), Etoposide (dose level 1), Etoposide (dose level 2), Paclitaxel, Pemetrexed, External beam radiation (dose level 1), External beam radiation (dose level 2), External beam radiation (hyperfractionated), Cisplatin (dose level 1), Cisplatin (dose level 2), External beam radiation (standard); Drug · Radiation
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 110 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 3
States / cities: Tucson, Arizona • Aurora, Colorado • Houston, Texas

Conditions: Epilepsy
Interventions: Brivaracetam; Drug
Lead sponsor: UCB PHARMA Inc. (US); Industry
Eligibility: 16 Years and older
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 46
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 38 more

Conditions: Migraine
Interventions: Lasmiditan, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 847 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 77
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 68 more

Conditions: Pain Associated With Fibromyalgia
Interventions: DS-5565, Pregabalin, Placebo tablet, Placebo capsule; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 1,301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 91
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 87 more

Conditions: Abdominal Aortic Aneurysm
Interventions: AFX EVAR AAA Graft System, FDA Approved EVAR AAA Graft Systems; Device
Lead sponsor: Endologix; Industry
Eligibility: 18 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 56
States / cities: Florence, Alabama • Huntsville, Alabama • Phoenix, Arizona + 49 more

Conditions: Elevated High-sensitivity C-Reactive Protein (hsCRP)
Interventions: Rosuvastatin, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years and older
Enrollment: 17,802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 431
States / cities: Birmingham, Alabama • Calera, Alabama • Columbiana, Alabama + 428 more

Conditions: Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions: Atezolizumab, Biopsy of Bladder, Cisplatin, Computed Tomography, Cystoscopy, Fluorouracil, Gemcitabine, Magnetic Resonance Imaging, Mitomycin, Quality-of-Life Assessment, Radiation Therapy, Survey Administration, Transurethral Resection of Bladder Tumor; Drug · Procedure · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 365
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 273 more

Conditions: Obesity, Overweight, Type 2 Diabetes
Interventions: Orforglipron, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 35
States / cities: Sun City West, Arizona • Tucson, Arizona • San Ramon, California + 31 more

Conditions: Cervical Ripening, Labor, Induced
Interventions: Misoprostol vaginal insert 100 mcg, Misoprostol vaginal insert 50 mcg, Dinoprostone vaginal insert (Cervidil); Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 49
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 43 more

Conditions: Relapsed/Refractory Diffuse Large B-cell Lymphoma
Interventions: Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy); Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 8
States / cities: Chandler, Arizona • Tucson, Arizona • Cerritos, California + 4 more

Conditions: Colitis, Ulcerative
Interventions: Ozanimod; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 36
States / cities: Phoenix, Arizona • Tucson, Arizona • Garden Grove, California + 30 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Injectable Product, Riociguat Pill; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: Rucaparib; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 58
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Ocrelizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 67
States / cities: Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: pioglitazone, inhaled human insulin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 110
States / cities: Ozark, Alabama • Tuscaloosa, Alabama • Vestavia Hills, Alabama + 100 more

Conditions: Postherpetic Neuralgia
Interventions: Retigabine, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 41
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 36 more

Search by objective public record fields.

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)

Growth and Tolerance of Infants Fed Infant Formulas

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

Evaluating the Neurocomputational Mechanisms of Explore-Exploit Decision Making in Older Adults

Safety and Efficacy Study of an Interactive Wound Dressing (KC002) for the Treatment of Diabetic Foot Ulcers

Durolane Versus Phosphate Buffered Saline (PBS) in Knee Osteoarthritis

Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation

RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment

A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Treatment of Pain Associated With Fibromyalgia

Post-Market Study to Assess Outcomes of Patients Treated With AFX System Compared to Other EVAR Devices

JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH

A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes

Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)